All News

Phase 3 data show an investigational 6-valent OspA-based Lyme vaccine prevents more than 70% of cases; regulatory submissions planned.

New AHA/ASA stroke guidance widens thrombolysis and EVT access, eases imaging, and updates BP/glucose targets—what frontline teams need now.

FDA approves orforglipron, a once-daily oral GLP‑1 for weight management, taken with food or coffee—simplifying obesity treatment.

The algorithm adds a new diabetes classification pathway and expands comorbidity-driven pharmacotherapy guidance, incorporating recent trial data on GLP-1 receptor agonists, SGLT2 inhibitors, and MASLD.

Phase 3 data show oral PCSK9 inhibitor enlicitide reduced LDL-C by 64.6% at 8 weeks vs oral nonstatins in high-risk patients.

New evidence suggests lowering LDL-C to 44 mg/dL with PCSK9 therapy may better protect high-risk patients with diabetes, aligning primary prevention targets with secondary prevention.

Phase 3b findings suggest that combining a GLP-1/GIP receptor agonist with IL-17 inhibition may improve both joint and metabolic outcomes in adults with psoriatic arthritis and obesity.

Once-weekly insulin makes injections simpler, boosts adherence, and lets clinics train patients fast—ideal for older adults.

ACC 2026: A new secondary analysis of the VESALIUS-CV study shows evolocumab cuts heart attacks, strokes and deaths in high‑risk patients with type 2 diabetes.

The approval of Foundayo (orforglipron) marks a formulation milestone in obesity pharmacotherapy, offering a once-daily pill free of the fasting requirements that may complicate adherence.

From new oral options for for psoriatic disease to once-weekly insulin, 5 FDA decisions with implications for primary care practice.

Your daily dose of the clinical news you may have missed.

Which patients are most likely to benefit from once-weekly insulin? Early insights on insulin icodec for adults with type 2 diabetes, here.

Test your knowledge of added sugar limits, processed food reduction, and label interpretation in the 2025–2030 Dietary Guidelines.

ACC 2026. Evolocumab reduced first CV events by 31% in high-risk diabetes without ASCVD, supporting earlier LDL-C intensification.

Your daily dose of the clinical news you may have missed.

From oral GLP-1s for obesity and T2D to a potential first new smoking cessation drug in 20 years, here are 5 FDA pipeline updates to put on your radar.